GG3 is a murine monoclonal antibody specifically targeting the stalk region of influenza hemagglutinin (HA), a key component of the influenza virus. It has been utilized in competitive ELISA (enzyme-linked immunosorbent assay) studies to detect cross-reactive, heterosubtypic neutralizing antibodies (nAbs) in human sera, particularly in the context of H7N9 infection .
Target specificity: Binds to conserved epitopes in the HA stalk region, distinguishing it from head-specific antibodies .
Mechanism of action: Competes with serum antibodies for HA binding, enabling quantification of stalk-specific immune responses .
Application: Used to confirm cross-group reactivity (e.g., between H1 and H5 subtypes) in post-infection sera .
GG3 has been instrumental in demonstrating that cross-reactive stalk-specific antibodies are predominantly elicited during infections like H7N9, rather than head-specific responses. For example:
Early-stage inhibition: Preincubation of HA with GG3 reduced binding activity in sera from H7N9-infected individuals, with peak inhibition observed during the early phase of infection .
Memory response: The inhibition effect plateaued in later stages, suggesting memory B-cell responses targeting the HA stalk .
| Parameter | Early Infection | Late Infection | Control Group |
|---|---|---|---|
| GG3-mediated inhibition | Significant reduction in binding activity | Reduced inhibition | Baseline levels |
| Source |
GG3’s ability to distinguish stalk-specific antibodies highlights its potential in:
Vaccine development: Identifying immunogens that induce broad heterosubtypic immunity .
Biomarker identification: Assessing cross-reactive antibody responses in individuals exposed to diverse influenza strains .
While GG3 has proven valuable in mapping HA stalk-specific responses, its utility is constrained by:
Limited structural data: Detailed epitope mapping and binding kinetics remain uncharacterized.
Species specificity: As a murine antibody, its relevance to human therapeutic applications is unexplored.